Frontiers in Oncology (Mar 2021)

Glycolysis and Fatty Acid Oxidation Inhibition Improves Survival in Glioblastoma

  • Kelly J. McKelvey,
  • Erica B. Wilson,
  • Susan Short,
  • Alan A. Melcher,
  • Michael Biggs,
  • Connie I. Diakos,
  • Connie I. Diakos,
  • Connie I. Diakos,
  • Viive M. Howell

DOI
https://doi.org/10.3389/fonc.2021.633210
Journal volume & issue
Vol. 11

Abstract

Read online

Glioblastoma (GBM) is the most aggressive adult glioma with a median survival of 14 months. While standard treatments (safe maximal resection, radiation, and temozolomide chemotherapy) have increased the median survival in favorable O(6)-methylguanine-DNA methyltransferase (MGMT)-methylated GBM (~21 months), a large proportion of patients experience a highly debilitating and rapidly fatal disease. This study examined GBM cellular energetic pathways and blockade using repurposed drugs: the glycolytic inhibitor, namely dicholoroacetate (DCA), and the partial fatty acid oxidation (FAO) inhibitor, namely ranolazine (Rano). Gene expression data show that GBM subtypes have similar glucose and FAO pathways, and GBM tumors have significant upregulation of enzymes in both pathways, compared to normal brain tissue (p < 0.01). DCA and the DCA/Rano combination showed reduced colony-forming activity of GBM and increased oxidative stress, DNA damage, autophagy, and apoptosis in vitro. In the orthotopic Gl261 and CT2A syngeneic murine models of GBM, DCA, Rano, and DCA/Rano increased median survival and induced focal tumor necrosis and hemorrhage. In conclusion, dual targeting of glycolytic and FAO metabolic pathways provides a viable treatment that warrants further investigation concurrently or as an adjuvant to standard chemoradiation for GBM.

Keywords